NCT02283632已完成不适用
A Trial of the Jejunal Diversion Procedure (Side-to-side Jejuno-jejunostomy) (Europe)
Ethicon Endo-Surgery1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2014年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Assess change in glycosylated hemoglobin A1c
研究概览
简要总结
This is a single site trial to assess metabolic effects in subjects after a Jejunal Diversion procedure was performed.
详细描述
The Jejunal Diversion procedure is an adaptation of a jejuno-jejunostomy, which is a surgical procedure often used to address a mix of pathological conditions. The safety of the Jejunal Diversion procedure is not in question, but rather understanding the gastrointestinal signalling effects. Up to 25 eligible subjects will be enrolled into the trial. Enrollment will stop once 15 subjects have undergone the Jejunal Diversion procedure
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •20 to 60 years of age (inclusive) on the date the ICD is signed
- •A BMI ≥ 27 kg/m2 and < 40 kg/m2
- •HbA1c ≥ 8% (63.9 mmol/mol) and ≤ 11% (96.7 mmol/mol)
- •C-peptide ≥ 3 ng/mL (0.999 nmol/L)
- •At least one of the following:
- •Systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, or on anti-hypertensive medication
- •HDL < 40 mg/dL (1.0344 mmol/L) (men) or < 50 mg/dL (1.293 mmol/L) (women), or on medication for low HDL
- •LDL > 100 mg/dL (2.586 mmol/L), or on medication for high LDL
- •TG ≥ 150 mg/dL (1.694 mmol/L) or on TG lowering medication treatment
- •FPG ≥ 100 mg/dL (5.556 mmol/L) or on medication for hyperglycemia or anti-T2DM
- •Able to comprehend and sign the EC-approved trial ICD
排除标准
- •Unable or unwilling to attend follow-up visits and examinations
- •History of drug and/or alcohol abuse within 2 years of Screening Visit
- •Any previous major GI surgery (e.g., any GI surgery with a resection, etc.) Examples of previous GI surgery allowed include: appendectomy, gall bladder surgery, liver biopsies, endoscopic procedures, etc.
- •Scheduled concurrent surgical procedure
- •Women of childbearing potential who are pregnant or lactating at the time of screening, at the time of surgery, or planning to become pregnant during the follow-up period
- •Psychiatric disorders that may affect compliance with the clinical trial, including dementia, active psychosis, severe depression, or history of suicide attempts
- •Any condition which precludes compliance with the trial, including:
- •Inflammatory diseases of the GI tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease or ulcerative colitis that have been active within the past 10 years
- •History of Hepatitis B or C
- •LADA (confirmed by positive GAD autoantibodies, IAA, and ICA)
- •Immunocompromised such as that resulting from chronic oral steroid use, cancer chemotherapeutic agents, or immune deficiency disorders
- •Screening laboratory tests with any of the following:
- •ALT and/or AST levels ≥ 4 times ULN according to laboratory normal ranges
- •Blood creatinine level ≥ 1.5 times ULN according to laboratory normal ranges
- •BUN level ≥ 1.5 times ULN according to laboratory normal ranges
- •Use of any of the following medications in the past 120 days:
- •Chronic steroid use
- •Prescription or over-the-counter medications or supplements with a primary indication known to cause or assist in weight reduction
- •Use of any of the following medications in the past 60 days:
- •a. Promotility agents
- •Any other medical condition or finding for which, at the discretion of the PI, the subject should be excluded
- •Participation in any other clinical trial (not to include registries or survey-only studies) within 30 days or 5 half lives of an investigational drug (which ever is longer), of Visit 1 (Screening Visit) and for the duration of the trial
结局指标
主要结局
Assess change in glycosylated hemoglobin A1c
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Trial of the Jejunal to Ileal Diversion Endoscopic Procedure (Side-to-Side Anastomosis)DiabetesNCT02839512GI Windows, Inc.10
招募中
不适用
Small Bowel DiversionType2 DiabetesObesityNCT06374368University of Ostrava80
已完成
不适用
Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes MellitusType 2 Diabetes MellitusObesityNCT04627103GI Windows, Inc.18
已完成
1 期
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis PatientsChronic Kidney Disease PatientsNCT06238388Haisco Pharmaceutical Group Co., Ltd.6
终止
2 期
A Pilot Study of Metabolic Effects of OmentectomyPatients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet TherapyAge 18-64 YearsNCT00565799NYU Langone Health11